BIO Scott Lowe

Scott Lowe

Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York US  |  CV

Lowe’s laboratory at Memorial Sloan Kettering Cancer Center studies tumor-suppressor networks controlling apoptosis and senescence and how their disruption influences malignant behavior. Their research is based on the premise that the path of cancer evolution dictates a tumor’s subsequent response to therapy and creates unique vulnerabilities that represent therapeutic opportunities. Throughout his career, Scott Lowe has made seminal contributions to the field of cancer and tumor suppression, including the identification of critical functions of the p53 tumor suppressor, landmark discoveries identifying the process of oncogene-induced senescence, as well as developing highly innovative genomic tools and mouse models to uncover the genetics of cancer progression and chemotherapeutic responsiveness. They use mouse models, RNA interference (RNAi), and cancer genomics to identify components of tumor suppressor gene networks and understand the molecular determinants of treatment response. The lab also uses temporally regulatable RNAi technology to identify genes required for tumor maintenance and to explore the mechanisms involved in tumor regression, including both cell intrinsic and extrinsic mechanisms.

See lecture